Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
April 2011, Vol 2, No 2
April 2011, Vol 2, No 2
Accelerating Growth in REMS Programs a Challenge for Oncologists
By
Daniel Denvir
ACCC Conference
April 2011, Vol 2, No 2
Addressing the 2011 Association of Community Cancer Centers annual meeting attendees,
Timothy Tyler, PharmD, FCSHP
, Director of Pharmacy Services at the Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, CA, outlined the considerable demands and complications that have been added to oncology care with the introduction of the Risk Evaluation and Mitigation Strategies (REMS) program for high-risk drugs.
Read Article
Oncologists Debate the Place of Pathways and Guidelines in Clinical Practice
By
Daniel Denvir
ACCC Conference
April 2011, Vol 2, No 2
Read Article
Implementing the HITECH Rules in Oncology Practices
By
Gena Cook
ACCC Conference
April 2011, Vol 2, No 2
Read Article
NCCN 2011 Clinical Guidelines Updates
By
Robert W. Carlson, MD
Clinical Guidelines
,
NCCN Conference
,
Policies & Guidelines
April 2011, Vol 2, No 2
Chairpersons of the various National Comprehensive Cancer Network (NCCN) tumor panels presented clinical practice updates at the recent 16th Annual Conference of the NCCN. Key updates, and relevant discussions, are highlighted.
Read Article
Denosumab a New Option for Preventing Skeletal-Related Events in Advanced Cancer
In the Literature
April 2011, Vol 2, No 2
Read Article
KRAS Mutation Predicts Treatment Outcomes of Anti-EGFR Therapies
In the Literature
April 2011, Vol 2, No 2
Read Article
National Projections: 27% Rise in Cost of Cancer Care in 2020
In the Literature
April 2011, Vol 2, No 2
Read Article
Ipilimumab a Powerful New Targeted Drug for Advanced Melanoma
FDA Approvals, News & Updates
April 2011, Vol 2, No 2
Applying its priority review route, the FDA approved the biologic medication ipilimumab (Yervoy; Bristol-Myers Squibb) as a second-line therapy for the treatment of patients with unresectable or metastatic melanoma.
Read Article
FDA Approved First Generic Docetaxel
FDA Approvals, News & Updates
April 2011, Vol 2, No 2
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma